Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/eUu23a2QDn https://t.co/RHDLTm9NMD